DK1082302T3 - En VLA-4-inhibitor: oMePUPA-V - Google Patents

En VLA-4-inhibitor: oMePUPA-V

Info

Publication number
DK1082302T3
DK1082302T3 DK99926019T DK99926019T DK1082302T3 DK 1082302 T3 DK1082302 T3 DK 1082302T3 DK 99926019 T DK99926019 T DK 99926019T DK 99926019 T DK99926019 T DK 99926019T DK 1082302 T3 DK1082302 T3 DK 1082302T3
Authority
DK
Denmark
Prior art keywords
omepupa
inhibitor
vla
cell
methylphenylamino
Prior art date
Application number
DK99926019T
Other languages
English (en)
Inventor
Wen-Cherng Lee
Alan Gill
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DK1082302T3 publication Critical patent/DK1082302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK99926019T 1998-05-28 1999-05-28 En VLA-4-inhibitor: oMePUPA-V DK1082302T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8706498P 1998-05-28 1998-05-28
PCT/US1999/011924 WO1999061421A1 (en) 1998-05-28 1999-05-28 A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (1)

Publication Number Publication Date
DK1082302T3 true DK1082302T3 (da) 2004-04-26

Family

ID=22202907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99926019T DK1082302T3 (da) 1998-05-28 1999-05-28 En VLA-4-inhibitor: oMePUPA-V

Country Status (31)

Country Link
US (1) US6495525B1 (da)
EP (1) EP1082302B1 (da)
JP (1) JP2002516309A (da)
KR (1) KR100636713B1 (da)
CN (1) CN1148350C (da)
AT (1) ATE256659T1 (da)
AU (1) AU764108B2 (da)
BG (1) BG65021B1 (da)
CA (1) CA2333656C (da)
CZ (1) CZ298413B6 (da)
DE (1) DE69913687T2 (da)
DK (1) DK1082302T3 (da)
EA (1) EA002988B1 (da)
EE (1) EE04639B1 (da)
ES (1) ES2211096T3 (da)
HK (1) HK1035726A1 (da)
HU (1) HUP0102255A3 (da)
IL (1) IL139967A (da)
IS (1) IS5737A (da)
MX (1) MXPA00011774A (da)
NO (1) NO317990B1 (da)
NZ (1) NZ509199A (da)
PL (1) PL198189B1 (da)
PT (1) PT1082302E (da)
SI (1) SI1082302T1 (da)
SK (1) SK285280B6 (da)
TR (1) TR200100190T2 (da)
UA (1) UA65623C2 (da)
WO (1) WO1999061421A1 (da)
YU (1) YU75500A (da)
ZA (1) ZA200007300B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
EP1034164B1 (en) * 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
JP2002524529A (ja) * 1998-09-14 2002-08-06 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CZ2002518A3 (cs) 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
ES2382806T3 (es) 2003-07-24 2012-06-13 Daiichi Sankyo Company, Limited Compuesto ácido ciclohexanocarboxílico
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) * 2006-03-08 2010-03-23 Microsoft Corporation Multi-cache cooperation for response output caching
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
PT3202789T (pt) 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
EP0506748B1 (en) 1989-12-22 1995-12-13 Commonwealth Scientific And Industrial Research Organisation Amino acids, peptides or derivatives thereof coupled to fats
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
ATE158589T1 (de) 1991-11-22 1997-10-15 Yeda Res & Dev Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen
WO1993012809A1 (en) 1991-12-24 1993-07-08 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
US5922755A (en) 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
SK8199A3 (en) * 1996-07-25 2000-04-10 Biogen Inc Cell adhesion inhibitors, preparation method thereof and pharmaceutical composition with their content

Also Published As

Publication number Publication date
MXPA00011774A (es) 2002-10-17
WO1999061421A1 (en) 1999-12-02
NZ509199A (en) 2003-10-31
DE69913687T2 (de) 2004-10-07
JP2002516309A (ja) 2002-06-04
CN1307561A (zh) 2001-08-08
DE69913687D1 (de) 2004-01-29
EP1082302B1 (en) 2003-12-17
CN1148350C (zh) 2004-05-05
EE04639B1 (et) 2006-06-15
PL198189B1 (pl) 2008-06-30
KR20010043906A (ko) 2001-05-25
HK1035726A1 (en) 2001-12-07
AU764108B2 (en) 2003-08-07
PT1082302E (pt) 2004-04-30
CZ298413B6 (cs) 2007-09-26
HUP0102255A3 (en) 2001-12-28
SK285280B6 (sk) 2006-10-05
EP1082302A1 (en) 2001-03-14
CA2333656A1 (en) 1999-12-02
NO20006023D0 (no) 2000-11-28
IS5737A (is) 2000-11-28
BG65021B1 (bg) 2006-12-29
ZA200007300B (en) 2002-02-27
SI1082302T1 (en) 2004-06-30
ES2211096T3 (es) 2004-07-01
NO20006023L (no) 2001-01-17
KR100636713B1 (ko) 2006-10-20
AU4219299A (en) 1999-12-13
IL139967A0 (en) 2002-02-10
SK18102000A3 (sk) 2001-07-10
US6495525B1 (en) 2002-12-17
IL139967A (en) 2005-11-20
PL344440A1 (en) 2001-11-05
UA65623C2 (en) 2004-04-15
EA002988B1 (ru) 2002-12-26
HUP0102255A2 (hu) 2001-11-28
BG105060A (en) 2001-08-31
CA2333656C (en) 2008-07-29
CZ20004425A3 (en) 2001-05-16
NO317990B1 (no) 2005-01-17
EE200000698A (et) 2002-06-17
EA200001236A1 (ru) 2001-06-25
TR200100190T2 (tr) 2001-05-21
ATE256659T1 (de) 2004-01-15
YU75500A (sh) 2002-12-10

Similar Documents

Publication Publication Date Title
DK1082302T3 (da) En VLA-4-inhibitor: oMePUPA-V
BR9908280A (pt) Inibidores de enzimas de fosfolipase
GEP20063956B (en) Cell adhesion inhibitors
UA39093C2 (uk) Похідні пептидів, що є інгібіторами еластази лейкоцитів людини, спосіб їх отримання та фармацевтична композиція
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
MD1507F2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
RO117913B1 (ro) Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
WO2001090138A3 (en) SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
DE69034070T2 (de) Racemisches Huperzin A
IS4627A (is) Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid
BR9912010A (pt) Polimorfo de um produto farmacêutico
AU2003271811A1 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
NO980296L (no) Forbedrede terapeutiske midler
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
NO20024616D0 (no) Ny fremgangsmåte ved syntese av N-[(S)-1-karboksybutyl]-(S)- alaninestere og anvendelse i syntese av perindopril
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
WO2000063350A3 (en) Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
MY137391A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
ES2173023A1 (es) Composicion farmaceutica con actividad inmunosupresora